Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sprout Pharmaceuticals, Inc
ClinicalTrials.gov Identifier:
NCT00360529
First received: August 3, 2006
Last updated: June 6, 2016
Last verified: June 2016
  Purpose
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Condition Intervention Phase
Sexual Dysfunctions, Psychological
Drug: flibanserin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America

Resource links provided by NLM:


Further study details as provided by Sprout Pharmaceuticals, Inc:

Primary Outcome Measures:
  • Satisfying Sexual Event Monthly Change From Baseline at Final Visit [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
    Change from baseline in the frequency of sexual satisfying events, as measured via e-Diary, standardized to a 28-day period. Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24.

  • Sexual Desire Monthly Change on Electronic Diary From Baseline at Final Visit [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]

    Change from baseline in eDiary Sexual Desire Monthly Total Score standardized to a 28-day period. Change from baseline calculated as the difference between the 4 week baseline period and Week 21 to Week 24. Patients recorded information daily throughout trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read "Indicate your most intense level of sexual desire in the last 24 hours/since your last visit." Potential responses included "no," "low," "moderate," or "strong", scored 0-3 (0 indicating no desire and 3 indicating the highest level of desire):

    0 = No desire

    1. = Low desire
    2. = Moderate desire
    3. = Strong desire

    Total score ranged from 0-84, with higher scores reflecting stronger desire). Monthly desire score was calculated as 28 x (sum of daily desire scores/number of responses).



Secondary Outcome Measures:
  • Female Sexual Distress Scale - Revised (FSDS-R) Total Score Change From Baseline at Final Visit [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]

    Change from baseline in the Female Sexual Distress Scale - revised (FSDS-R) Total Score with a seven day recall period.

    The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The maximum total score of the FSDS-R is '52' (score of minimum of 0 and maximum of 4 for each item) and indicates the maximum level of sexual distress (the higher the score, the higher the level of reported sexual desire).


  • Female Sexual Distress Scale - Revised (FSDS-R) Question 13 Score Change From Baseline at Final Visit [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
    Change from baseline in the FSDS-R Question 13 (Bothered by low sexual desire). The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The scoring for item 13 is from 0-4, with 4 indicating the highest level of sexual distress.

  • Female Sexual Functioning Index (FSFI) Desire Domain Score Change From Baseline at Final Visit [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
    Female Sexual Function Inventory (FSFI) Desire Domain assesses sexual desire or interest with 2 questions ranging from 1 (very low) to 5 (very high). The domain total score is multiplied by 0.6 yielding scores ranging from 1.2 to 6 (higher scores = higher level of desire or interest).

  • Female Sexual Functioning Index (FSFI) Total Score Change From Baseline at Final Visit [ Time Frame: Baseline, Week 24 ] [ Designated as safety issue: No ]
    The FSFI© is a self-administered questionnaire to assess FSD, which consists of 19 questions that are scored from '0' to '5.' The scale contains six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate higher levels of the domain assessed. The total score is a weighted average of the six domains, each contributing a maximum of 6 points to the total, so the minimum score is 2, while the maximum score of FSFI© is 36.

  • Patient Benefit Evaluation [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The Patient Benefit Evaluation is a single question asking the patient whether or not she experienced a meaningful benefit from the study medication during the trial. This question ("Overall, do you believe that you have experienced a meaningful benefit from the study medication?") was asked upon treatment discontinuation.


Enrollment: 880
Study Start Date: July 2006
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: fibanserin
flibanserin 50 mg q.h.s.
Drug: flibanserin
flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Other Names:
  • flibanserin 50 mg
  • flibanserin 100mg
  • placebo
Experimental: flibanserin
flibanserin 100 mg q.h.s.
Drug: flibanserin
flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Other Names:
  • flibanserin 50 mg
  • flibanserin 100mg
  • placebo
Placebo Comparator: placebo
placebo q.h.s.
Drug: flibanserin
flibanserin placebo versus 50 mg qhs versus 100 mg qhs
Other Names:
  • flibanserin 50 mg
  • flibanserin 100mg
  • placebo

Detailed Description:
This trial was designed as a prospective, multicenter trial containing a 24-week, randomized, double blind, placebo controlled, parallel-group period that assessed the effects of flibanserin (maximum total daily dose: 100 mg q.d.) compared with placebo in premenopausal women with HSDD, determined by Diagnostic and Statistical Manual IV- Text Revision (DSM IV-TR®) criteria. Three hundred patients were to be randomized to each treatment group. This trial examined the safety and efficacy of flibanserin compared to placebo for 24 weeks.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women who are 18 years of age and older.
  2. Premenopausal women having regular menstrual periods who have HSDD (decreased sexual desire), generalized acquired type, according to DSM IV-TR criteria.
  3. Patient must meet minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress.
  4. Patients must be willing to try to have sexual activity (e.g., any act involving direct genital stimulation) at least once monthly.
  5. Patients must be willing and able to use an electronic diary (eDiary) on a daily basis (e.g., have access to a working land line telephone for daily data transmissions).
  6. At the Baseline Visit, patients must have complied with eDiary use adequately.
  7. Patients must be in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least 1 year prior to the Screen Visit. The partner is expected to be physically present at least 50% of each month.
  8. Patients must have used a medically acceptable method of contraception for at least 3 months before the Baseline Visit (Visit 2) and continue to use that medically acceptable method of contraception during the trial.
  9. In the investigators opinion, patients must be reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them.
  10. Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss their sexual functioning with the investigative staff.
  11. Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Screen Visit.

Exclusion Criteria:

  1. Patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening.
  2. Patients whose sexual function was affected (enhanced or worsened) in the investigators opinion by any medication within 30 days before the Screen Visit and anytime prior to the Baseline Visit.
  3. Patients with a history of drug dependence or abuse within the past one year.
  4. Patients with a history of multiple severe reactions (i.e., allergic or oversensitivity to usual doses) to drugs that affect the brain.
  5. Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin.
  6. Patients who meet accepted diagnostic criteria for sexual disorders that would interfere with improvement in HSDD (sexual aversion, substance-induced sexual problems, urge to live as a man, etc.
  7. Patients who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the patients response to treatment.
  8. Patients who have entered the menopausal transition or menopause or have had a hysterectomy.
  9. Patients with findings at the Screen Visit of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female organs.
  10. Patients who are breast feeding or have breastfed within the last 6 months prior to the Baseline Visit.
  11. Patients who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit.
  12. Patients with a history of Major Depressive Disorder within 6 months prior the Screen Visit, a score indicating depression on a depression scale, a history of suicide attempt, or current suicidal ideation evident at the Screen or Baseline Visit.
  13. Patients with a history of any other psychiatric disorders that could impact sexual function, risks patients safety, or may impact compliance.

<truncated>

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00360529

  Show 54 Study Locations
Sponsors and Collaborators
Sprout Pharmaceuticals, Inc
Investigators
Study Chair: Sprout Pharmaceuticals Sprout Pharmaceuticals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sprout Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT00360529     History of Changes
Other Study ID Numbers: 511.71  VIOLET 
Study First Received: August 3, 2006
Results First Received: March 14, 2012
Last Updated: June 6, 2016
Health Authority: Canada: Health Canada
United States: Food and Drug Administration

Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological
Mental Disorders

ClinicalTrials.gov processed this record on September 30, 2016